Argenx completes Forte acquisition, adding FB102 with near-term data catalysts
Aug 27, 2026, 8:54 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
An accretive pipeline expansion via an in-class asset with upcoming data catalysts typically supports higher valuation and potential multiple expansion, especially for a leader in immunology like ARGX. Historical examples: successful acquisitions with late-stage data readouts around data catalysts have driven short- to mid-term upside for target-name acquirers.
AI summary
What happened, with direct paths to the underlying reporting
Argenx completed the Forte Biosciences takeover, adding FB102, a first-in-class anti-CD122 antibody, to its immunology portfolio. FB102 has shown proof-of-concept in vitiligo and celiac disease, with Phase 2 celiac data expected in 2H2026 and vitiligo readouts in 2026. The deal broadens ARGX's pipeline and creates near-term data catalysts that could lift upside potential.
Argene completes Forte acquisition; FB102 adds first-in-class anti-CD122.
Forte shareholders paid $77 per share; ~87% tendered.
Forte becomes ARGX subsidiary; Forte stock delisted from Nasdaq.
Deal expands ARGX’s immunology pipeline with T/NK-cell–targeting mechanism.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
argenx announced positive topline Phase 3 ALKIVIA results for VYVGART Hytrulo in autoimmune myositis (IMNM+DM), meeting the primary endpoint with a 15.4-point mean TIS improvement…
argenx is acquiring Forte Biosciences for $77 per share in cash, valuing Forte at about $2.2 billion. Forte's FB102 anti-CD122 antibody has Phase 1b signals in vitiligo and celiac…
Argenx updated its Phase 3 myositis plan, separating IMNM and DM analyses and dropping PM. HC Wainwright remains bullish on Vyvgart, citing IMNM's potential to exceed $1B in sales…
The FDA has approved a significant label expansion for Argenx's VYVGART, allowing its use in all serotype adult patients with generalized myasthenia gravis. This comes after posit…
